OSCR
Oscar Health, Inc.
OSCR has the edge over QURE overall, supported by stronger fundamentals and lower modeled downside.
QURE
uniQure N.V.
QURE offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
QURE Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Strong |
QURE's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
QURE PE Valuation
QURE has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
QURE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect QURE's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over QURE on earnings quality, reporting a profit while its opponent remains loss making.
QURE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.52 | +$0.86 |
| Q2 2026 | -$4.02 | -$0.11 |
| Q1 2026 | -$3.49 | +$0.89 |
| Q4 2025 | -$3.46 | +$1.46 |
| Q3 2025 | -$4.38 | +$0.57 |
| Q2 2025 | -$3.91 | +$2.01 |
| Q1 2025 | -$4.38 | +$1.82 |
| Q4 2024 | -$4.92 | +$1.55 |
QURE is still losing money, but less than at its worst: $3.52 per share over the past year, against $6.47 at its worst in late 2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over QURE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over QURE on profitability, with a higher operating margin.
QURE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.2M | +40% |
| Q2 2026 | $5.8M | +11% |
| Q1 2026 | $3.6M | +127% |
| Q4 2025 | $5.6M | +6.6% |
| Q3 2025 | $3.7M | +62% |
| Q2 2025 | $5.3M | -53% |
| Q1 2025 | $1.6M | -82% |
| Q4 2024 | $5.2M | -22% |
QURE's revenue is recovering but still below its 2021 peak: $5M last quarter, up 40% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1020% | +359 points |
| Q2 2026 | -894% | -60 points |
| Q1 2026 | -1284% | +1226 points |
| Q4 2025 | -918% | -40 points |
| Q3 2025 | -1379% | +380 points |
| Q2 2025 | -834% | -438 points |
| Q1 2025 | -2510% | -1871 points |
| Q4 2024 | -878% | +45 points |
QURE's operating margin was −1020% last quarter, up 359 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over QURE on cash generation, producing positive trailing cash flow while its opponent burns cash.
QURE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.8M | -$31.5M |
| Q2 2026 | -$29M | +$11.1M |
| Q1 2026 | -$38.4M | +$5.8M |
| Q4 2025 | -$77.7M | -$24.8M |
| Q3 2025 | -$16.3M | +$20.6M |
| Q2 2025 | -$40.2M | -$6.8M |
| Q1 2025 | -$44.2M | +$18.7M |
| Q4 2024 | -$52.9M | -$1.3M |
QURE has burned cash in almost every quarter: −$193M over the past year, against −$154M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
QURE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.5% | +3.7M shares |
| 1 year | +19% | +11.4M shares |
| 3 years | +46% | +22.1M shares |
| 5 years | +51% | +23.7M shares |
| Available history | +75% | +29.9M shares |
QURE has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
QURE Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2022 | -1.4x | Net Cash |
| Q4 2021 | -1.4x | Net Cash |
QURE has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
QURE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.4 | Neutral |
| Stochastic | 10.8 | Oversold |
QURE's weekly RSI is 41 (neutral) and its Stochastic is 11 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
QURE PE vs Healthcare Sector
| Metric | QURE | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
QURE has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over QURE on trend strength, trading above more of its moving averages.
QURE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.0 | 1.3% below |
| 20 week MA | $36.6 | 33% below |
| 50 week MA | $28.6 | 14% below |
| 100 week MA | $24.8 | 0.6% below |
| 200 week MA | $17.3 | 43% above |
QURE has fallen below most of its moving averages, though it's still 43% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over QURE on returns for 2026, with the stronger performance.
QURE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $72.5 | $38.1 | -47% |
| 2021 | $38.1 | $22.3 | -42% |
| 2022 | $22.3 | $23.3 | +4.7% |
| 2023 | $23.3 | $6.77 | -71% |
| 2024 | $6.77 | $17.5 | +158% |
| 2025 | $17.5 | $24.8 | +42% |
| 2026 YTD | $24.8 | $24.6 | -0.7% |
QURE's yearly returns have swung widely, from +158% in 2024 to −71% in 2023. It's down 0.7% so far in 2026.